Skip to search formSkip to main contentSkip to account menu

Xgeva Injectable Product

National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

1.7 ML denosumab 70 MG/ML Injection [Xgeva]denosumab Injection [Xgeva]
InjectablesXgeva

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors
Denosumab (XGEVA®) is a recombinant, fully human IgG2 monoclonal antibody directed against the receptor activator of nuclear… 
2011
2011
Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study
Abstract 2483 Introduction: Hypercalcemia of malignancy (HCM) is a serious complication in patients with advanced cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)